<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2004696-9375-4C0A-AD85-77C5C8426BD2"><gtr:id>F2004696-9375-4C0A-AD85-77C5C8426BD2</gtr:id><gtr:firstName>Klaus</gtr:firstName><gtr:surname>Okkenhaug</gtr:surname><gtr:orcidId>0000-0002-9432-4051</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000H260"><gtr:id>03A66BC4-944E-4BD8-B2A4-B03FEF0D4E01</gtr:id><gtr:title>PhD studentship: Role of PI3K in autoimmunity and infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000H260</gtr:grantReference><gtr:abstractText>Autoimmune diseases such as Rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis can be caused by the immune system which instead of fighting pathogens, turns on different organs in the body. The aim of this project is to determine if inhibition of an enzyme called PI3K p110delta can be used to alleviate autoimmunity. At the same time, we will determine if inhibition of p110delta increases risk of infection with common bacteria. These studies will help determine whether p110delta is a good drug target.</gtr:abstractText><gtr:fund><gtr:end>2014-08-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-08-08</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>26682</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Based on the discovery of Activated PI3K Delta Syndrome (APDS) GSK has announced a clinical trial of their Pi3Kd inhibitor GSK2269557.
This is supported by and MRC-MICA award, but build on work we have done on PI3Kd, including discovery that APDS leads to hyperactive PI3Kd in T cells.</gtr:description><gtr:id>0339A25A-201B-4325-A2D3-455A37347AF9</gtr:id><gtr:impact>Another trial has been announced by Novartis.</gtr:impact><gtr:outcomeId>56ddc5b12f55d5.89211360</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cinical trial of GSK</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02593539</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1EA3AD8A-6DB5-4739-8F29-A2C382D04D54</gtr:id><gtr:title>Phosphoinositide 3-kinase d gene mutation predisposes to respiratory infection and airway damage.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5d405946584af030b04daeee4c67d"><gtr:id>28a5d405946584af030b04daeee4c67d</gtr:id><gtr:otherNames>Angulo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5447882a4b8d97.98440481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93B53622-AA92-4031-85C9-97ADD4C2A3BE</gtr:id><gtr:title>The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.</gtr:title><gtr:parentPublicationTitle>The open rheumatology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8b863a357145e7c52c5c0e6fb3e263"><gtr:id>2b8b863a357145e7c52c5c0e6fb3e263</gtr:id><gtr:otherNames>Banham-Hall E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3129</gtr:issn><gtr:outcomeId>5447882c0c3bb4.81374015</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000H260</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>